Broad Institute of Harvard and MIT; Cambridge, MA USA ; Department of Medical Oncology; Cancer Vaccine Center; Dana-Farber Cancer Institute; Boston, MA USA.
Broad Institute of Harvard and MIT; Cambridge, MA USA ; The Division of Allergy, Immunology and Rheumatology; Department of Medicine; Massachusetts General Hospital; Boston, MA USA.
Oncoimmunology. 2014 Jun 25;3:e29311. doi: 10.4161/onci.29311. eCollection 2014.
Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient's tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.
基于新抗原的癌症疫苗旨在针对每个患者肿瘤中出现的独特免疫原性突变，为这一陷入困境的治疗方法注入了新的活力。数据继续表明新抗原在癌症的免疫控制中的重要性。尽管存在制造复杂性、未解决的问题和进一步改进的需求，但新抗原疫苗目前正在进行临床评估。
Zotero 插件